ALFA Finder| Revenue growth | FY26: 37.1% YoY (₹2053.1cr); Q4FY26: 134.9% YoY (₹788.7cr). |
|---|---|
| Margins | EBITDA margin expanded to 29.4% in FY26 (up 650 bps). |
| Order book | Growth in new project orders for current and next FY. |
| Demand visibility | Strong visibility in short to medium term for commercial molecules. |
| Management confidence | High; citing good business visibility and strong note ending FY26. |
Growth
FY26 Revenue grew 37.1% to ₹2,053.1cr; PAT surged 40% to ₹363.1cr. Q4FY26 EBITDA margin reached 40.5%.
Outlook
Investing in Peptide manufacturing and a new R&D center; FY26 Capex outflow was ₹397cr.
Risks
Specialty segment remains subdued due to specific molecule performance; working capital and inventory fluctuations noted.
Earnings Call filed with NSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹20,404.00
- Market cap
- ₹26,178 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 57.9×Sector 43.8×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q2 income and EBITDA fell sharply YoY, and PAT dropped 47%. Management blames commercial lumpiness, says H1 was in line, and declined to quantify FY27 growth or give molecule-level detail.
Neuland Laboratories Investor Presentation: Key Takeaways
Q2FY27 income Rs457.2 Cr (-11.4% YoY), PAT Rs51.1 Cr (-47.0%), EBITDA margin 22.9% on operating deleverage. H1FY27 income Rs1107.2 Cr (+35.6%), PAT Rs198.5 Cr (+80.2%). Capex-led R&D and peptide build-out.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
Neuland Laboratories Q2 FY27 Results: Net Profit ₹51.6 Cr, Down 46.7% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹449.7 Cr (-12.6% YoY) and net profit of ₹51.6 Cr (-46.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.6 Cr · -46.7% YoY
Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.